Business
AN INDEPENDENT EVALUATION CONFIRMS THE CLINICAL AND ORGANIZATIONAL BENEFITS OF THE MEDHERIZE PLATFORM IN BREAST ONCOLOGY
KDA Group Inc. (TSXV: KDA) ("KDA" or the "Corporation"), a leader in innovative technological solutions for healthcare professionals, is pleased to announce the results of an independent evaluation of its digital platform Medherize, conducted by the Breast Disease Centre of CHU de Québec – Université Laval (Hôpital du Saint-Sacrement). Carried out among 243 patients with breast cancer on targeted oral therapies (CDK4/6 inhibitors) between September 2025 and March 2026, the evaluation demonstrate
About this update from Kda Group Inc.
THETFORD MINES, QC, June 18, 2026 /CNW/ - KDA Group Inc. (TSXV: KDA) ("KDA" or the "Corporation"), a leader in innovative technological solutions for healthcare professionals, is pleased to announce the results of an independent evaluation of its digital platform Medherize, conducted by the Breast Disease Centre of CHU de Québec – Université Laval (Hôpital du Saint-Sacrement). Carried out among 243 patients with breast cancer on targeted oral therapies (CDK4/6 inhibitors) between September 2025 and March 2026, the evaluation demonstrates measurable benefits, for both patients and care teams. Medherize is a web and mobile application that centralizes the monitoring of breast oncology patients. It acts as a triage and prioritization tool for clinical results, highlights those requiring an intervention, and integrates with the Quebec Health Record (DSQ) for the real-time retrieval of laboratory results. Concrete benefits for patients A significant easing of the care teams' workload These results occur in a context of strong volume growth: prescriptions of CDK4/6 inhibitors at CHU de Québec rose from 257 in 2023 to 503 in 2025, driven by the broadening of the indications for these treatments. The gains in adherence and follow-up are relevant to all stakeholders in the oncology ecosystem. Security and protection of personal information The protection of patients' personal information was built into the design of Medherize. The data are hosted on servers located in Quebec, certified ISO 27001, and are encrypted in transit and at rest. The platform was designed in compliance with Law 25 respecting the protection of personal information. Exchanges between the institution, patients, and community pharmacies take place through secure messaging. "These results confirm what we set out to achieve in designing the Adherize+ platform with the Medherize module: to refocus teams' attention on clinically significant situations while strengthening patient autonomy. That an independent evaluation conducted in a hospital setting demonstrates this is an important validation for the future," said Jean-Marc Léveillé, Fellow CRIA, President and Chief Executive Officer of KDA. Next steps Considering these results, the clinical team of the Breast Disease Centre recommends making Medherize a permanent tool for monitoring patients on CDK4/6 i...